Alzheimer-kór: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• BDNF 0
• TDP-43 2
• PI3K 0
• BACE1 0
• GLP-1 1
• MAPK 0
• PPAR 0
• AMPK 0
• mTOR 0
• PSEN1 1
• STING 0
• ERK 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• SGLT2 0
• HMGB1 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

15+ intézményből 15, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F31

  The role of the default mode network in representing and remembering mental states

  Boston College· Chestnut Hill, Egyesült Államok· 35 733 USD awarded in fiscal year 2026· until 2028. okt.

• U.S. Department of Veterans Affairs · I01

  SleepSMART for Veterans with Insomnia and Mild Cognitive Impairment: A Randomized Clinical Trial

  Va San Diego Healthcare System· San Diego, Egyesült Államok· until 2031. szept.

• U.S. Department of Veterans Affairs · IK2

  Cognitive Risk Profiles Among Aging Veterans: Harnessing Big Data for Precision Medicine

  Va San Diego Healthcare System· San Diego, Egyesült Államok· until 2031. szept.

• NIH NIA · R03

  Improve and Validate Amyloid Pathology Visualization and Analysis in Intact Brain Samples

  Massachusetts General Hospital· Boston, Egyesült Államok· 329 220 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NIA · R01

  Enhanced Mapping of Alzheimer's Disease Risk Loci Using Multimodal RNAseq Data

  Emory University· Atlanta, Egyesült Államok· 653 912 USD awarded in fiscal year 2026· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Neuroinflammation and Virus Imaging for Smart Therapeutic Approaches (NEUROVISTA)

  Umea Universitet· Umea, Svédország· EU contribution 236 340 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Németország· EU contribution 202 125 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Warfare and Agricultural Resilience Nexus in the Ancient Mediterranean (6th. BC - 4th c. AD) (WARNex)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 252 729 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Attentional Control and Mapping in Spatial Navigation: Defining Behavioral Fingerprints for Early Alzheimer’s Risk Detection (SPATIALOS)

  Universitat Jaume I de Castellon· Castellon De La Plana, Spanyolország· EU contribution 209 915 EUR· until 2029. ápr.

• European Commission (Horizon Europe) · HORIZON-ERC

  Principles of UFMylation-driven antibacterial defence (UBACT)

  Universite de Geneve· Geneve, Svájc· EU contribution 1 898 233 EUR· until 2032. ápr.

  The disease is named only in the funder's project summary, not in the title.

10 of 5135 running projects, newest first. Listed amounts together: 4,3 Mrd USD + 321,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Alzheon Inc.· Frissítve: 2026. jún. 25.

  “Sponsor business decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

  NCT04187547· Cerecin· Frissítve: 2023. ápr. 14.

  “Study replaced with a new study”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease

  NCT07864623· Eisai Inc.· Forrás

• Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

  NCT07146412· HudsonAlpha Institute for Biotechnology· Forrás

• A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)

  NCT06682767· Cedars-Sinai Medical Center· Forrás

• ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness

  NCT07679906· Firalis SA· Forrás

• Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype

  NCT03876314· University of North Carolina, Greensboro· Forrás

• ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

  NCT07392723· Michal Schnaider Beeri, Ph.D.· Forrás

• Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results

  NCT06459583· Banner Health· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 86
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 176
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 229
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 676
• Magnetic Resonance Imaging 1001
• Machine Learning 253
• Deep Learning 166
• Cohort Studies 536
• Genome-Wide Association Study 216

• Genetic Determinants of Vascular Dementia: Blood Metabolite Associations and Candidate Therapeutic Target Prioritization.

  Genet Epidemiol, 2026. dec.

• Genetic Liability to Opioid Use Disorder and Dementia-Related Biological Pathways: A Mendelian Randomisation Study.

  Int J Geriatr Psychiatry, 2026. nov.

• Evaluating the Impacts of Inflammatory Proteins on the Risk of Alzheimer's Disease.

  Mol Neurobiol, 2026. okt.

• Genetic evidence supports a cortical neuroprotective role of GLP-1 receptor activation in Alzheimer's disease: A drug-target Mendelian randomization study.

  Alzheimers Dement, 2026. okt.

• Associations of Blood Lipid Traits with Cognitive-Related Outcomes and Their Sensitivity to APOE-Region Instrumental Variables: A Mendelian Randomization and Colocalization Study.

  Genes (Basel), 2026. szept.

• CRP-albumin-lymphocyte index and multisystem diseases: a phenome-wide Mendelian randomization study.

  Mol Genet Genomics, 2026. szept.

• Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis.

  Cell Mol Neurobiol, 2026. szept.

• Alzheimer disease and lichen planus: A Mendelian randomization analysis.

  Medicine (Baltimore), 2026. szept.

• Multilevel genomic, transcriptomic, and epidemiologic evidence linking diabetic retinopathy to Alzheimer disease.

  J Glob Health, 2026. szept.

• Genetic evidence suggests a protective role of immunoglobulin M in Alzheimer's disease.

  Alzheimers Dement, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.